Literature DB >> 17043496

Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis.

H Ralph Schumacher1.   

Abstract

Rheumatic diseases are among the most frequent causes of pain and disability. Effective management of rheumatic diseases including osteoarthritis (OA), ankylosing spondylitis (AS), and gouty arthritis requires an understanding of the underlying disease mechanisms.Symptoms of OA result from both mechanical factors and elements of inflammation. Current management strategies target both of these factors and generally consist of nonpharmacologic and pharmacologic interventions, including use of nonspecific nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2-specific inhibitors (coxibs), which have analgesic and antiinflammatory properties. Other approaches include intraarticular hyaluronate and the use of alternative therapies under investigation such as acupuncture or glucosamine.Disease mechanisms in AS involve enthesitis, an inflammation at the site of insertion of ligaments, tendons, or joint capsules to bone. Posture and exercise are important nonpharmacologic strategies that may be made easier with the use of NSAIDs or coxibs. Recently developed therapies, including tumor necrosis factor inhibitors, target the underlying disease mechanisms and have demonstrated dramatic symptomatic effects. Disease-modifying effects still need to be established.In gout, hyperuricemia leads to crystal-induced inflammation in some patients. Etoricoxib, one of the newer coxibs, has shown promise in treating acute gout, with efficacy similar to indomethacin, the current standard NSAID often used in these patients. Oral or intraarticular steroids can also be considered. For chronic care uricosurics can be beneficial if renal function is normal and excretion is not excessive, but allopurinol is used most often. Nonpharmacologic modalities, such as rest and cold applications, are useful for acute episodes, and lifestyle modification in the form of diet can also play a role in chronic disease management.

Entities:  

Year:  2004        PMID: 17043496     DOI: 10.1097/01.rhu.0000131745.37852.bb

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  3 in total

Review 1.  Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.

Authors:  Shaobo Zhang; Yibao Zhang; Peng Liu; Wei Zhang; Jing-Lin Ma; Jing Wang
Journal:  Clin Rheumatol       Date:  2015-06-24       Impact factor: 2.980

2.  Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs.

Authors:  Anna Eisenstein; Brandon K Hilliard; Scott D Pope; Cuiling Zhang; Pranali Taskar; Daniel A Waizman; Kavita Israni-Winger; Hui Tian; Harding H Luan; Andrew Wang
Journal:  Immunity       Date:  2022-05-18       Impact factor: 43.474

Review 3.  Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology.

Authors:  Roy Altman; Bill Bosch; Kay Brune; Paola Patrignani; Clarence Young
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.